<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01366014</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-797-223</org_study_id>
    <secondary_id>C4411007</secondary_id>
    <nct_id>NCT01366014</nct_id>
  </id_info>
  <brief_title>A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study, involving a 4-week treatment period, designed to test the ability of&#xD;
      investigational study drug ARRY-371797 to reduce pain in patients with moderate to severe&#xD;
      pain due to osteoarthritis (OA) of the knee, and to further evaluate the drug's safety.&#xD;
      Approximately 150 patients from the US will be enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the efficacy of the study drug (versus placebo) in terms of change from baseline to week 4 in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score (index knee).</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of the study drug (versus placebo) in terms of change from baseline to week 4 in the WOMAC stiffness and physical function subscale scores (index knee).</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, electrocardiograms and vital signs.</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetics of the study drug and metabolite as determined by plasma concentrations.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>ARRY-371797</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone HCl ER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-371797, p38 inhibitor; oral</intervention_name>
    <description>multiple dose, single schedule</description>
    <arm_group_label>ARRY-371797</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral</intervention_name>
    <description>multiple dose, single schedule</description>
    <arm_group_label>Oxycodone HCl ER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; oral</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of OA of the knee, based on American College of Rheumatology (ACR) criteria,&#xD;
             confirmed by X-ray (K-L Grade II/III within the last year).&#xD;
&#xD;
          -  At least moderate or severe pain due to OA in one knee.&#xD;
&#xD;
          -  On nonsteroidal anti-inflammatory drug (NSAID) 28 days previous to study start and&#xD;
             willing to continue on NSAID throughout study.&#xD;
&#xD;
          -  Discontinuation of opioids prior to study start.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Current or recent infection in the last 7 days; infection requiring hospitalization or&#xD;
             parenteral antibiotics within the last 6 months; history of or currently active&#xD;
             tuberculosis, hepatitis B or C, or human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Surgery on the index knee within the previous 6 months.&#xD;
&#xD;
          -  Trauma or other surgeries within the previous 8 weeks.&#xD;
&#xD;
          -  Specific abnormal laboratory values or electrocardiogram abnormalities.&#xD;
&#xD;
          -  Gastrointestinal surgery that may interfere with motility or absorption.&#xD;
&#xD;
          -  On non-stable dose of bisphosphonates, or any prior denosumab or parathyroid hormone&#xD;
             (PTH) therapies.&#xD;
&#xD;
          -  Prior parenteral tumor necrosis factor (TNF) inhibitor or anti-nerve growth factor&#xD;
             (NGF) therapies.&#xD;
&#xD;
          -  Intramuscular, intravenous or oral corticosteroids within the previous 6 weeks.&#xD;
&#xD;
          -  Intra-articular corticosteroids in the index knee within the previous 8 weeks or&#xD;
             viscosupplementation in the index knee within the previous 4 months.&#xD;
&#xD;
          -  Currently enrolled in or participated in another clinical trial within the previous 3&#xD;
             months.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <disposition_first_submitted>June 6, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>June 6, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 14, 2013</disposition_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <keyword>pain</keyword>
  <keyword>NSAID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

